Bufexamac
Bufexamac structure
|
Common Name | Bufexamac | ||
|---|---|---|---|---|
| CAS Number | 2438-72-4 | Molecular Weight | 223.268 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C12H17NO3 | Melting Point | 161 - 162ºC | |
| MSDS | Chinese USA | Flash Point | N/A | |
|
Erythema-multiforme-like, urticarial papular and plaque eruptions from bufexamac: report of 4 cases.
Contact Dermatitis 31(2) , 97-101, (1994) 4 patients developed an erythema-multiforme-like reaction following acute contact dermatitis from 2 different bufexamac-containing topical preparations. Histologically, the lesions did not show changes that were typical of erythema multiforme. Patch testing g... |
|
|
[A severe epicutaneous test reaction to the bufexamac in a hemorrhoidal therapeutic preparation].
Dtsch. Med. Wochenschr. 124(40) , 1168-70, (1999) A 49-year-old woman presented with acute perianal vesicular/bullous contact dermatitis. Other areas were over the trunk, face, neck and wrists. She reported occasional application of an ointment (Mastu S) to treat her hemorrhoids.Patch tests (basic series, an... |
|
|
[A common and insidious side-effect: allergic contact dermatitis caused by bufexamac used in the treatment of dermatitis. Results from the Information Network of Departments of Dermatology (IDVK)].
Dtsch. Med. Wochenschr. 130(50) , 2881-6, (2005) Bufexamac is a non-steroidal, anti-inflammatory drug used in the topical treatment of atopic dermatitis, stasis dermatitis and perianal eczema. The substance is known to cause severe allergic contact dermatitis (ACD) as an adverse effect (AE), which may be in... |
|
|
In vitro photobiochemical characterization of sulfobutylether-β-cyclodextrin formulation of bufexamac.
J. Pharm. Biomed. Anal. 55(3) , 591-6, (2011) The present study aimed to modulate the photoreactivity of bufexamac, with a focus on photostability and phototoxicity, by forming an inclusion complex with sulfobutylether-β-cyclodextrin (SBECD). The photobiochemical properties of bufexamac were evaluated by... |
|
|
Examinations of the antioxidative properties of the topically administered drug bufexamac reveal new insights into its mechanism of action.
J. Pharm. Pharmacol. 55(10) , 1379-88, (2003) The effect of bufexamac on UV-irradiation-induced lipid peroxidation was investigated. Linolenic acid was used as a model lipid. Bufexamac was shown to be capable of reducing the amount of lipid peroxidation. The quantification was carried out by the thiobarb... |
|
|
Allergic contact dermatitis to topical preparations of bufexamac.
Australas. J. Dermatol. 53(3) , 207-10, (2012) In Australia bufexamac is mainly used for pharmacist-initiated local treatment of various dermatoses. The European Medicines Agency's Committee for Medicinal Products for Human Use recently recommended that marketing authorisation for bufexamac-containing pre... |
|
|
[Bufexamac-induced pigmented purpuric eruption].
Hautarzt 60(5) , 424-7, (2009) We report on a case of a bufexamac-induced allergic contact dermatitis with hematogenous dissemination presenting with the clinical and histological picture of a pigmented purpuric eruption. To our knowledge this is the first report on a bufexamac-induced pig... |
|
|
Allergic contact dermatitis syndrome from bufexamac for nursing infant.
Dermatitis 23(4) , 185-6, (2012)
|
|
|
Contact dermatitis caused by bufexamac sparing the eruption of herpes zoster.
J. Dermatol. 39(4) , 405-7, (2012)
|
|
|
Acute generalized exanthematous pustulosis induced by bufexamac in an atopic girl.
Contact Dermatitis 58(4) , 247-8, (2008)
|